How should an infant with bronchopulmonary dysplasia receiving hydrocortisone therapy be weaned off the steroid?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 10, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Weaning Hydrocortisone in Infants with Bronchopulmonary Dysplasia

Taper hydrocortisone gradually over 3-10 days by reducing the dose by 10-20% every other day based on clinical response, monitoring closely for adrenal insufficiency and respiratory deterioration during the wean. 1

Specific Tapering Protocol

The most practical approach based on available evidence involves:

  • Initial dose reduction: After completing the therapeutic course (typically 1 mg/kg/day divided into two doses), begin tapering by decreasing the dose by 10-20% every other day 1
  • Duration of taper: The taper should extend over 3-10 days depending on the total duration of therapy and clinical stability 1
  • Standard regimen example: If using 0.5 mg/kg every 12 hours, taper to 0.25 mg/kg every 12 hours for the final 3 days before discontinuation 2

Critical Monitoring During Weaning

Respiratory status: Watch for increased oxygen requirements, increased work of breathing, or need for escalation of ventilatory support, as these may indicate premature weaning 2

Adrenal function: Monitor for signs of adrenal insufficiency including hypotension, hypoglycemia, hyponatremia, and hyperkalemia, particularly if hydrocortisone was used for >7-10 days 2

Blood pressure and glucose: Check blood pressure regularly during the taper, as hypertension is a known complication that may persist or worsen during weaning 2, 3

Evidence-Based Rationale

The tapering approach is necessary because:

  • HPA axis suppression: Prolonged corticosteroid use can suppress the hypothalamic-pituitary-adrenal axis, requiring gradual withdrawal to allow recovery 2
  • Rebound inflammation: Abrupt discontinuation may lead to rebound pulmonary inflammation and respiratory deterioration in infants with BPD 2
  • Safety profile: Hydrocortisone has demonstrated a more favorable neurodevelopmental safety profile compared to dexamethasone, with no adverse effects on neurodevelopmental outcomes at 18-22 months 2

Clinical Decision Points

If respiratory status worsens during taper: Slow the taper rate or temporarily increase the dose back to the previous level, then attempt a more gradual reduction 1

If signs of adrenal insufficiency appear: Consider stress-dose hydrocortisone coverage (2-3 times maintenance) during acute illness or procedures, and extend the taper duration 2

Minimum effective duration: Most studies used 10-12 day courses with 3-day tapers, suggesting this represents a reasonable minimum treatment duration before initiating the wean 2, 4

Important Caveats

Avoid abrupt discontinuation: Never stop hydrocortisone suddenly after more than 7 days of therapy, as this significantly increases the risk of adrenal crisis 2

Timing considerations: If the infant was started on hydrocortisone in the first 2 weeks of life for BPD prevention, the standard 10-12 day course with 3-day taper is appropriate 2, 4. For later "rescue" therapy (after 3 weeks), the observational data suggests starting at 1 mg/kg twice daily and tapering by 10-20% every other day based on clinical response 1

Concomitant medications: Be aware that infants receiving indomethacin or ibuprofen for patent ductus arteriosus closure may have increased risk of gastrointestinal perforation when combined with early hydrocortisone, though this risk appears lower with hydrocortisone than dexamethasone 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.